《大行報告》高盛下調上海醫藥(02607.HK)目標價至12.58元 評級「沽售」
高盛發表研究報告指,上海醫藥(02607.HK)今年第三季純利按年增長22%,達到11.2億元人民幣,低於該行16億元人民幣的預期,相信主要是由於第七輪帶量採購導致毛利率下降至11.9%,以及期內投資收益較低;而第三季收入按年增長12.9%,則勝預期。
高盛將上藥2022至2024年各年淨利潤預測各下調6.7%、7.1%及7.1%,以反映利潤率壓力不斷增加,維持「沽售」評級,目標價由13.37元下調至12.58元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.